EMPA-REG Data Will Boost Jardiance's Role In Combination Therapy, Lilly Says
Executive Summary
Large outcomes trial showing a cardiovascular benefit with empagliflozin could shift the treatment landscape to earlier use of the SGLT2 inhibitor in combination therapy rather than replacing treatment with metformin and other agents, Lilly Diabetes President Conterno predicts.
You may also be interested in...
FDA Warning On SGLT-2 Drugs Raises Specter Of Labeling Change
FAERS reports identify cases of diabetic ketoacidosis, ordinarily rare in type 2 diabetes, which were not associated with high blood sugar levels.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.